Journal
EUROPEAN JOURNAL OF CANCER
Volume 42, Issue 18, Pages 3095-3102Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2006.05.041
Keywords
ubiquitin; multiple myeloma; leukaemia; lymphoma; bortezomib; Ub system-targeted drugs
Categories
Ask authors/readers for more resources
Ubiquitin (Ub) is a small protein modifier involved in cellular functions such as cell cycle, apoptosis, cell signalling, endocytosis, transcription and DNA repair. Ubiquitin operates as a reversible and highly versatile regulatory signal, which may be read and interpreted by an expanding number of Ub-binding domains (UBD). There is accumulating evidence that mutations or altered expression of ubiquitylating or de-ubiquitylating enzymes as well as of Ub-binding proteins affect crucial mediators of such functions and are found in several malignancies. Here we discuss how oncogenic alterations in the Ub system can be targeted by anti-cancer therapies. (c) 2006 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available